RESUMO
Fenfluramine reduces hunger and promotes body weight loss by increasing central serotonin (5-HT) signaling. More recently, neuropeptides have been linked to the regulation of feeding behavior, metabolism and body weight. To examine possible interactions between 5-HT and neuropeptides in appetite control, fenfluramine (200 nmol/0.5 µl/side) was administered directly into the hypothalamic paraventricular nuclei (PVN) of male rats. Bilateral fenfluramine produced significant hypophagia and increased expression of PVN corticotropin releasing factor (CRF) mRNA and neuropeptide Y (NPY) mRNA in the arcuate nucleus within the first hour after drug administration. Fenfluramine's effects on feeding behavior and mRNA expression were blocked by PVN injections of a 5-HT(1-2) receptor antagonist, metergoline (15 nmol/0.5 µl/side). These data suggest that 5-HT neurons targeting hypothalamic paraventricular CRF neurons may participate in an appetite control circuit for reducing food intake.
Assuntos
Hormônio Liberador da Corticotropina/biossíntese , Comportamento Alimentar/fisiologia , Núcleo Hipotalâmico Paraventricular/metabolismo , Núcleo Hipotalâmico Paraventricular/fisiologia , Serotonina/fisiologia , Animais , Regulação do Apetite/efeitos dos fármacos , Regulação do Apetite/fisiologia , Núcleo Arqueado do Hipotálamo/metabolismo , Hormônio Liberador da Corticotropina/fisiologia , Interações Medicamentosas , Comportamento Alimentar/efeitos dos fármacos , Fenfluramina/administração & dosagem , Fenfluramina/antagonistas & inibidores , Fenfluramina/farmacologia , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Microinjeções , Neuropeptídeo Y/biossíntese , Núcleo Hipotalâmico Paraventricular/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-DawleyRESUMO
This study examined the acute changes in feeding and drinking behaviours of free-feeding and free-drinking pigeons, in response to local injections of metergoline (MET, 5-HT(1/2) receptor antagonist; 7 and 20 nmol), GR46611 (GR, 5-HT(1B/1D) agonist; 2 and 6 nmol) or vehicle, into two components of the arcopallium: the nucleus taeniae of the amygdala (TnA) and the arcopallium intermedium (AI). In the TnA, the highest MET dose elicited a short-lived hyperphagy, without affecting drinking or non-ingestive behaviours during the first hour after injection. In contrast, all MET doses promptly increased drinking when injected in the AI, without affecting feeding; this effect was still evident 3 and 24 h after the treatment. When injected in the TnA, the highest GR dose promptly increased both food and water intake; these effects persisted 24 h after the treatments. GR injections in the AI evoked long-lasting increases in drinking, but not in feeding. Injections of these drugs into other arcopallial nuclei evoked no significant ingestive effects. These data indicate the presence of a tonic inhibitory influence of serotonergic inputs, partially mediated by 5-HT(1B/1D) receptors, on feeding- and drinking-related TnA circuits and on mechanisms controlling drinking in the AI. Compared to data from the rodent medial amygdala, our results suggest that a tonic inhibitory 5-HTergic control of feeding (but not drinking) behaviour, mediated by 5-HT(1/2) receptors and exerted in the medial amygdaloid area, may represent a broadly conserved functional attribute in the amniote brain, but probably involves many important taxa-specific neural mechanisms.
Assuntos
Tonsila do Cerebelo/fisiologia , Encéfalo/fisiologia , Ingestão de Líquidos/fisiologia , Ingestão de Alimentos/fisiologia , Receptores 5-HT1 de Serotonina/metabolismo , Receptores 5-HT2 de Serotonina/metabolismo , Acrilamidas/administração & dosagem , Acrilamidas/farmacologia , Tonsila do Cerebelo/efeitos dos fármacos , Análise de Variância , Animais , Encéfalo/efeitos dos fármacos , Cateterismo , Columbidae , Relação Dose-Resposta a Droga , Ingestão de Líquidos/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Indóis/administração & dosagem , Indóis/farmacologia , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Receptor 5-HT1B de Serotonina/metabolismo , Receptor 5-HT1D de Serotonina/metabolismo , Agonistas do Receptor 5-HT1 de Serotonina , Antagonistas do Receptor 5-HT1 de Serotonina , Antagonistas do Receptor 5-HT2 de Serotonina , Antagonistas da Serotonina/administração & dosagem , Antagonistas da Serotonina/farmacologia , Agonistas do Receptor de Serotonina/administração & dosagem , Agonistas do Receptor de Serotonina/farmacologia , Fatores de TempoRESUMO
The present study examined changes in spontaneous behavior of free-feeding pigeons in response to local injections of metergoline (MET, an antagonist of 5-HT(1/2) receptors; 5, 10 and 20 nmol), GR-46611 (GR, a 5-HT(1B/1D) agonist; 0.6 and 6 nmol) or vehicle into the paraventricular hypothalamic nucleus (PVN). When infused into the PVN, MET and GR promptly and reliably elicited feeding at their higher doses, without affecting drinking or non-ingestive behaviors (locomotion, exploration, preening, sleep) during the first hour after injection. Both GR- and MET-evoked ingestive responses were associated only with an increase in feeding duration, with no changes in latency to start feeding. In a second series of experiments, the effective doses of MET (20 nmol) and GR (6 nmol) were injected into other diencephalic areas. This exploratory study revealed that intense feeding responses to both MET and GR local injections are also observed in the n. medialis hypothalami posterioris and in the adjacent n. lateralis hypothalami posterioris (PMH/PLH complex, in the caudoventral hypothalamus) and in the n. magnocellularis preopticus (PPM, in the caudal preoptic region). The behavioral profiles associated with these hyperphagic responses were nucleus-specific: in the PMH/PLH, MET-induced feeding was accompanied by an increase in total feeding duration and by a reduction in the latency to start feeding, while ingestive responses evoked by MET in the PPM were associated only with an increase in feeding duration (similar to that observed in the PVN experiments). No ingestive effects were observed after intracerebroventricular (ICV, lateral ventricle) injections of MET (10, 30, 100 or 300 nmol), while ICV injections of GR (3, 15 or 30 nmol) increased feeding only at the higher dose [Da Silva RA, De Oliveira ST, Hackl LPN, Spilere CI, Faria MS, Marino-Neto J, Paschoalini MA. Ingestive behaviors and metabolic fuels after central injections of 5-HT1A and 5-HT1D/1B receptors agonists in the pigeon. Brain Res, 2004;1026:275-283]. These data indicate the presence of a tonic inhibitory influence on feeding behavior exerted by 5-HT afferents on these hypothalamic areas, and suggest that these inputs, possibly mediated by non-rodent-type 5-HT1D/1B receptors, can affect both satiety and satiation mechanisms.
Assuntos
Acrilamidas/farmacologia , Comportamento Alimentar/efeitos dos fármacos , Indóis/farmacologia , Metergolina/farmacologia , Núcleo Hipotalâmico Paraventricular/efeitos dos fármacos , Antagonistas da Serotonina/farmacologia , Acrilamidas/administração & dosagem , Análise de Variância , Animais , Columbidae , Relação Dose-Resposta a Droga , Comportamento Alimentar/fisiologia , Indóis/administração & dosagem , Masculino , Metergolina/administração & dosagem , Microinjeções , Núcleo Hipotalâmico Paraventricular/fisiologia , Receptores de Serotonina/classificação , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/fisiologia , Antagonistas da Serotonina/administração & dosagemRESUMO
The purpose of this study was to investigate the abortifacient effects of high doses of metergoline when administered to pregnant beagle bitches during the second half of gestation and to define the endocrine effects of this treatment as represented by plasma progesterone and estradiol concentrations. Previously, metergoline had been shown to be incompletely luteolytic and induced abortion in only one of eight pregnant bitches when 0.4-0.5 mg/kg were administered twice daily for 5 days from Days 18 to 20 of diestrus. Nine pregnancies in six beagle bitches were used for the present study. Three bitches were treated in each of two consecutive pregnant cycles. Metergoline was administered at a dose of 0.6 mg/kg per os twice daily, starting on Day 28 after the cytological onset of diestrus. Abortion was induced in eight of the nine treated pregnancies and started after 3-23 days of treatment (mean 12.5 days, S.D. 6.4 days). The abortions were completed within 0.5-8 days (mean 2.2 days, S.D. 2.7 days). There were no side effects associated with metergoline treatment and none of the abortions was associated with complications that required intervention. In the single bitch that did not abort, an ovarian granulosa cell tumor was discovered when the single fetus had to be removed surgically at term. Plasma progesterone concentrations declined after the start of metergoline administration in all pregnancies but levels below 4.8 nmol/l were required for successful abortions. Plasma estradiol concentrations showed a tendency to decline and fluctuate concurrently with the plasma progesterone levels. However, suppression of plasma estradiol concentrations by metergoline was not as complete as the suppression of progesterone and did not seem a prerequisite for abortion. The hormone profiles and treatment period required for abortion tended to be similar for both cycles of the three bitches that were treated during two consecutive pregnancies. This suggests a bitch effect on the factors that determine the efficacy of metergoline to induce abortion. The large variation and length of the treatment period that was required until abortion commenced was probably related to the relatively early start of treatment compared to other studies. The results of this investigation suggest that, similar to other prolactin suppressing ergot derivatives, metergoline causes complete luteolysis and can be used to reliably induce abortion only during the last 3 weeks of gestation.
Assuntos
Abortivos/administração & dosagem , Cães/sangue , Estradiol/sangue , Idade Gestacional , Metergolina/administração & dosagem , Progesterona/sangue , Aborto Animal/induzido quimicamente , Animais , Feminino , GravidezRESUMO
BACKGROUND: Total gastrectomy often results in early satiety and loss of body weight. Serotonin inhibits food intake, and postprandial serotonin release is increased after total gastrectomy. Serotonin might contribute to early satiety and loss of body weight after total gastrectomy. METHODS AND MATERIALS: Food intake and body weight were investigated with an automated recording system in gastrectomized rats 1-12 months postoperatively. Rats were treated with metergoline, a 5-hydroxytryptamine (5-HT)(1/2) receptor antagonist, two different 5-HT(3) receptor antagonists, a combination of metergoline and devazepide, a cholecystokinin (CCK) a receptor antagonist, or vehicle. In addition, metergoline or vehicle was applied continuously by an intraperitoneal osmotic minipump for 7, 28, or 84 days after total gastrectomy. RESULTS: Metergoline treatment resulted in a dose-dependent increase in food intake in gastrectomized rats. 5-HT(3) receptor antagonist treatment had no effect, and devazepide in addition to metergoline did not further stimulate food intake. Metergoline increased food intake at 1, 3, and 6 months postoperatively by up to 45% (24-h cumulative food intake [FI], 6 months: vehicle 3.83 +/- 0.10, metergoline 5.52 +/- 0.15 g/100 g body weight (BW), P < 0.0001). Chronic metergoline treatment for 7, 28, or 84 days significantly increased food intake after total gastrectomy compared to vehicle treatment (FI 7 days: vehicle 30.83 +/- 0.71, metergoline 36.27 +/- 0.85 g/100 g BW; P < 0.0002; average weekly FI during 28 days; vehicle 31.23 +/- 0.22, metergoline 36.83 +/- 0.33 g/100 g BW, P < 0.0001; average weekly FI during 84 days: vehicle 33.02 +/- 0.59, metergoline 35.07 +/- 0.48 g/100g BW, P < 0.008), and there was a significant body weight increase compared to vehicle treatment (7 days: DeltaBW vehicle -0.7 +/- 1.2 g vs DeltaBW metergoline 9.0 +/- 2.1 g, P < 0.001; 28 days: DeltaBW vehicle 0.3 +/- 2.2 vs DeltaBW metergoline 13.0 +/- 2.3, P < 0.001; 84 days: DeltaBW vehicle 25.7 +/- 10.2 vs DeltaBW metergoline 49.5 +/- 7.2, P < 0.04). Treatment for 84 days resulted in a significant body weight gain, while vehicle treatment had no effect (vehicle: 438 +/- 11 g vs 464 +/- 12 g, P < 0.2, n.s.; metergoline: 448 +/- 9 g vs 498 +/- 10 g, P < 0.007). CONCLUSIONS: Inhibition of food intake by serotonin might contribute to early satiety and loss of body weight after total gastrectomy.
Assuntos
Peso Corporal/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Gastrectomia , Metergolina/farmacologia , Antagonistas da Serotonina/farmacologia , Animais , Devazepida/farmacologia , Esquema de Medicação , Combinação de Medicamentos , Antagonistas de Hormônios/farmacologia , Masculino , Metergolina/administração & dosagem , Período Pós-Operatório , Ratos , Ratos Sprague-Dawley , Receptor de Colecistocinina A , Receptores da Colecistocinina/antagonistas & inibidores , Antagonistas da Serotonina/administração & dosagemRESUMO
A role for serotonin in season affective disorder (SAD) has been explored with a variety of serotonergic pharmacologic agents. The authors initially hypothesized that metergoline, a nonspecific serotonin antagonist, would exacerbate depressive symptoms. In a small, open-label pilot study, the authors observed the opposite effect. They decided to follow up on this finding with this formal study. The study followed a double-blind, randomized cross-over design. Sixteen untreated, depressed patients with SAD received single oral doses of metergoline 8 mg and of placebo, spaced 1 week apart. Fourteen patients were restudied after 2 weeks of light treatment. Depression ratings using the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version were performed at baseline and at 3 and 6 days after each intervention. These data were analyzed by baseline-corrected repeated measures with analysis of variance. In the off-lights condition, severity of depression was diminished after metergoline compared with placebo administration (p = 0.001). Patient daily self-ratings suggested that the peak effect occurred 2 to 4 days after study drug administration. In contrast, after 2 weeks of treatment with bright artificial light, metergoline did not demonstrate a significant effect on mood. These data suggest that single doses of metergoline may have antidepressant effects that last several days. Possible mechanisms include 5-hydroxytryptamine(2) receptor downregulation and dopamine agonism.
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Metergolina/administração & dosagem , Transtorno Afetivo Sazonal/tratamento farmacológico , Antagonistas da Serotonina/administração & dosagem , Adulto , Antidepressivos/efeitos adversos , Terapia Combinada , Estudos Cross-Over , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/psicologia , Agonistas de Dopamina/administração & dosagem , Agonistas de Dopamina/efeitos adversos , Método Duplo-Cego , Regulação para Baixo/efeitos dos fármacos , Feminino , Humanos , Masculino , Metergolina/efeitos adversos , Pessoa de Meia-Idade , Fototerapia , Receptores de Serotonina/efeitos dos fármacos , Transtorno Afetivo Sazonal/diagnóstico , Transtorno Afetivo Sazonal/psicologia , Antagonistas da Serotonina/efeitos adversosRESUMO
We have recently reported that bilateral infusions of the 5-HT receptor antagonist metergoline (MET) into the posterior basolateral amygdala (pBLA) elicit feeding in female rats tested at mid-light cycle. The present study was performed to determine whether (1) testing at two different phases of the estrous cycle, and/or (2) the palatability of the food might modify this effect. Subjects were 18 adult females with bilateral pBLA cannulae. Following familiarization with Froot Loops cereal, a within-subjects design tested all animals for 1- and 2-h food intake under 2 Drug (0.3 nmol MET vs. Vehicle), 2 Estrous Cycle (diestrus vs. estrus) and 2 Food (lab chow vs. Froot Loops) conditions. Rats weighed more at diestrus than at proestrus (P<.05) or estrus (P<.005). Multivariate analyses of variance (MANOVAs) revealed a preference for Froot Loops over lab chow (P<.0001). MET increased feeding regardless of food type (P<.0001). Rats ate more Froot Loops (P<.01), but not lab chow, at diestrus vs. estrus. A three-way interaction (P<.05) showed rats ate more during the first hour in estrus than in diestrus to lab chow but not Froot Loops. These data suggest pBLA MET differentially affects feeding over the estrous cycle depending on the palatability of food available.
Assuntos
Tonsila do Cerebelo/efeitos dos fármacos , Tonsila do Cerebelo/fisiologia , Ciclo Estral/fisiologia , Comportamento Alimentar/efeitos dos fármacos , Comportamento Alimentar/fisiologia , Alimentos , Antagonistas da Serotonina/farmacologia , Tonsila do Cerebelo/anatomia & histologia , Animais , Peso Corporal/efeitos dos fármacos , Peso Corporal/fisiologia , Feminino , Preferências Alimentares/fisiologia , Metergolina/administração & dosagem , Metergolina/farmacologia , Microinjeções , Ratos , Ratos Sprague-Dawley , Antagonistas da Serotonina/administração & dosagemRESUMO
Moclobemide is an antidepressant which affects the monoaminergic neurotransmitter system through a reversible inhibition of monoamine oxidase (MAO), preferentially type A. We examined the antinociceptive effects of moclobemide alone and in conjunction with specific opioid, adrenergic and serotonergic antagonists, using the mouse-tail flick test. Intraperitoneal moclobemide produced a dose-dependent antinociceptive effect with an ED50 of 69.1 mg/kg. Tests with selective antagonists yielded positive results only for yohimbine (P < 0.001), implying a noradrenergic mechanism of action in the moclobemide antinociceptive effect. This was confirmed by the coadministration of moclobemide with inactive doses of prototype agonists of the opioid, adrenergic and serotonergic systems. Only clonidine, an alpha2 agonist, significantly shifted (8-fold) the dose response curve of moclobemide. We conclude that there is a selective involvement of the alpha2 adrenergic pathways in the moclobemide-induced antinociceptive effect and a lesser involvement (if any) of the opioid, serotonergic and alpha1 adrenergic mechanisms. More research is needed to establish a possible role for moclobemide in pain management.
Assuntos
Analgésicos , Benzamidas/farmacologia , Vias Neurais/efeitos dos fármacos , Norepinefrina/fisiologia , Animais , Benzamidas/administração & dosagem , Clonidina/administração & dosagem , Clonidina/farmacologia , Relação Dose-Resposta a Droga , Esquema de Medicação , Injeções Intraperitoneais , Injeções Espinhais , Injeções Subcutâneas , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Camundongos , Camundongos Endogâmicos ICR , Moclobemida , Inibidores da Monoaminoxidase , Morfina/administração & dosagem , Morfina/farmacologia , Naloxona/administração & dosagem , Naloxona/farmacologia , Receptores Adrenérgicos alfa 2/efeitos dos fármacos , Receptores Adrenérgicos alfa 2/fisiologia , Serotonina/administração & dosagem , Serotonina/farmacologia , Ioimbina/administração & dosagem , Ioimbina/farmacologiaRESUMO
In a controlled, randomised, prospective, clinical study, the effect of prolactin suppression and clinical course of the lactation suppressors Bromocriptine and Metergoline were investigated. During 7 months 150 patients were studied. 81 of those patients, who did not nurse, were treated by Bromocriptine (primary lactation suppression: n = 62, secondary suppression: n = 19) and 69 of the patients were treated by Metergoline (primary suppression: n = 54, secondary suppression: n = 15). The drugs were administrated orally to all subjects, dosed 2 x 2.5 mg/d of Bromocriptine for 14 days and 3 x 4 mg/d of Metergoline for 10 days, starting in average after 13 hours. Puerperal suppression of prolactine were compared with randomised breast feeding subjects (n = 30). In Bromocriptine treated women the average plasma prolactin level decreased from 78.4 +/- 22 ng/ml to 17.0 +/- 3.3 ng/ml during five days of treatment. In Metergoline treated women the plasma prolactin level decreased from 129.7 +/- 15.1 ng/ml to 56.9 +/- 10.0 ng/ml during the first days of treatment. Prolactin level of breast feeding subjects decreased from 233.6 +/- 21.4 ng/ml to 185.8 +/- 23.7 ng/ml during the same period (p < 0.05). There is no statistical significancy of clinical difference of both drugs, but a statistical trend was seen. With Bromocriptine treated women were suppressed efficiently in 71 of 81 cases, 10 refused. Refusals were divided in two quality levels, level I with subjects with moderate complaints and little puerperal lactation, level II with subjects with considerable complaints including strong puerperal lactation. With Metergoline suppressed women, treatment was efficiently in 51 of 69 cases, but refusals of level I were observed in 11 cases and refusals of level II were observed in 7 cases. The results show that Bromocriptine and Metergoline are effective on suppression of lactation. Under the current drug dose of Metergoline an advantage of Bromocriptine were observed. Only further studies could investigate, whether an adaptation of drug dose would improve the clinical efficiency of Metergoline.
Assuntos
Bromocriptina/administração & dosagem , Lactação/efeitos dos fármacos , Metergolina/administração & dosagem , Administração Oral , Adulto , Pressão Sanguínea/efeitos dos fármacos , Bromocriptina/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Humanos , Metergolina/efeitos adversos , Prolactina/sangue , Estudos Prospectivos , Resultado do TratamentoRESUMO
d-Fenfluramine (0.63 mg/kg i.p.), a serotonin (5-hydroxytryptamine, 5-HT) releaser and re-uptake inhibitor, reduced the eating caused by neuropeptide Y (235 pmol) injected into the paraventricular nucleus of the hypothalamus. The 5-HT1 and 5-HT2 receptor antagonist metergoline (1.0 and 2.0 mg/kg i.p.) and the 5-HT1A and 5-HT1B receptor antagonist (+/-)-cyanopindolol (3.0 and 8.0 mg/kg s.c.) significantly antagonized the effect of d-fenfluramine. The 5-HT2A and 5-HT2C receptor antagonist mesulergine (0.1 and 0.3 mg/kg s.c.) and the 5-HT2A receptor antagonist ketanserin (2.5 and 5.0 mg/kg i.p.) did not significantly modify the effect, nor did the 5-HT1A and 5-HT1B receptor antagonist (-)-propranolol (20-40 nmol), injected bilaterally into the paraventricular nucleus of the hypothalamus. The results suggest that d-fenfluramine reduces neuropeptide Y's hyperphagia by indirectly stimulating 5-HT1B receptors outside the paraventricular nucleus of the hypothalamus.
Assuntos
Ingestão de Alimentos/efeitos dos fármacos , Fenfluramina/farmacologia , Neuropeptídeo Y/farmacologia , Núcleo Hipotalâmico Paraventricular/efeitos dos fármacos , Receptores de Serotonina/efeitos dos fármacos , Análise de Variância , Animais , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Interações Medicamentosas , Ergolinas/administração & dosagem , Ergolinas/farmacologia , Fenfluramina/administração & dosagem , Fenfluramina/antagonistas & inibidores , Hiperfagia/induzido quimicamente , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Injeções Intraperitoneais , Injeções Subcutâneas , Ketanserina/administração & dosagem , Ketanserina/farmacologia , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Neuropeptídeo Y/administração & dosagem , Núcleo Hipotalâmico Paraventricular/fisiologia , Pindolol/administração & dosagem , Pindolol/análogos & derivados , Pindolol/farmacologia , Ratos , Ratos Sprague-Dawley , Receptor 5-HT1B de Serotonina , Receptores de Serotonina/metabolismo , Antagonistas da Serotonina/administração & dosagem , Antagonistas da Serotonina/farmacologiaRESUMO
Effects of the non-selective 5-hydroxytryptamine (5-HT) receptor agonist m-chlorophenylpiperazine (m-CPP) on the nociceptive responsiveness in a hot plate and tail flick tests were examined in mice. Intraperitoneal administration of m-CPP (1-10 mg/kg) produced a dose-dependent antinociception in both those tests; the effect of m-CPP in the hot plate test was stronger. The antinociceptive effect of m-CPP in either test was abolished by pretreatment with mesulergine (2 mg/kg), ritanserin (1-2 mg/kg), 5-HT2A/5-HT2C receptor antagonists, and metergoline (0.5-2 mg/kg), a non-selective 5-HT receptor antagonist. On the other hand, spiperone (0.25-0.5 mg/kg), a dopamine, 5-HT1A and 5-HT2A receptor antagonist; pindolol (4-8 mg/kg), a beta-adrenoceptor, 5-HT1A and 5-HT1B receptor antagonist and zacopride (0.1-1 mg/kg) a 5-HT3 receptor antagonist, did not affect the analgesia induced by m-CPP. Neither of the drugs used as putative receptor antagonists changed the nociceptive responsiveness in mice. The obtained results suggest that the analgesia induced by m-CPP is mediated by 5-HT2C receptors.
Assuntos
Analgesia , Compostos Bicíclicos Heterocíclicos com Pontes , Piperazinas/farmacologia , Receptores de Serotonina/efeitos dos fármacos , Antagonistas da Serotonina/farmacologia , Agonistas do Receptor de Serotonina/farmacologia , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/farmacologia , Análise de Variância , Animais , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Benzamidas/administração & dosagem , Benzamidas/farmacologia , Compostos Bicíclicos com Pontes/administração & dosagem , Compostos Bicíclicos com Pontes/farmacologia , Relação Dose-Resposta a Droga , Interações Medicamentosas , Ergolinas/administração & dosagem , Ergolinas/farmacologia , Injeções Intraperitoneais , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Camundongos , Medição da Dor , Limiar da Dor/efeitos dos fármacos , Pindolol/administração & dosagem , Pindolol/farmacologia , Piperazinas/administração & dosagem , Piperazinas/metabolismo , Ratos , Receptores de Serotonina/metabolismo , Ritanserina/administração & dosagem , Ritanserina/farmacologia , Antagonistas da Serotonina/administração & dosagem , Agonistas do Receptor de Serotonina/administração & dosagem , Agonistas do Receptor de Serotonina/metabolismo , Espiperona/administração & dosagem , Espiperona/farmacologiaRESUMO
This study tested whether a new serotonin (5-HT1B) agonist, 3-(1,2,5,6-tetrahydro-4-pyridyl)-5-propoxy-pyrrolo[3,2-b]pyridine (CP-93,129), could be used to study the potential role of 5-HT1B receptors in the secretion of adrenocorticotropic hormone (ACTH), prolactin, and renin. CP-93,129 has a high affinity for 5-HT1B receptors but low affinity for other 5-HT receptor subtypes. In addition, CP-93,129 does not readily cross the blood-brain barrier. The secretion of ACTH, prolactin, and renin is known to be increased after activation of 5-HT receptors. ICV injections of CP-93,129 (100 micrograms/kg) increased the plasma concentrations of ACTH, prolactin, and renin. CP-93,129 also increased blood pressure and reduced heart rate. To determine whether these effects of CP-93,129 are centrally mediated, we compared them with IP injection of the same dose of CP-93,129. IP-injected CP-93,129 did not alter blood pressure or heart rate and did not elevate plasma prolactin and renin concentrations. To determine whether 5-HT1B receptors mediate the central effects of CP-93,129, rats were pretreated with the 5-HT antagonists l-propranolol or metergoline prior to ICV injections of doses of CP-93,129 (0-100 micrograms/kg). The 5-HT1A/1B/2A/2C antagonist metergoline (0.5 mg/kg, IP) failed to inhibit the CP-93,129-induced elevation of ACTH, prolactin, or renin concentrations. In contrast, the 5-HT1A/1B/beta antagonist l-propranolol (20 micrograms/kg, ICV) inhibited the renin but not the ACTH or prolactin responses to ICV CP-93,129.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Hormônio Adrenocorticotrópico/sangue , Pressão Sanguínea/efeitos dos fármacos , Prolactina/sangue , Piridinas/farmacologia , Pirróis/farmacologia , Renina/sangue , Agonistas do Receptor de Serotonina/farmacologia , Serotonina/fisiologia , Animais , Injeções Intra-Arteriais , Injeções Intraperitoneais , Injeções Intraventriculares , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Propranolol/administração & dosagem , Propranolol/farmacologia , Piridinas/administração & dosagem , Piridinas/antagonistas & inibidores , Pirróis/administração & dosagem , Pirróis/antagonistas & inibidores , Ratos , Ratos Sprague-Dawley , Agonistas do Receptor de Serotonina/administração & dosagem , Agonistas do Receptor de Serotonina/antagonistas & inibidoresRESUMO
Previous research has shown that systemic injections of the nonselective serotonin (5-HT) antagonist metergoline (MET) can stimulate feeding in both rats and humans. Five experiments were conducted to determine if this drug would elicit feeding in otherwise satiated rats after direct injections into the brain. In experiment 1, intraventricular infusions of 100 nmol MET produced reliable enhancements of feeding for 1 h compared with control infusions of a 5% tartaric acid (vehicle) solution. In experiment 2, a dose-response study of 0, 50, 100, and 150 nmol MET intraventricularly revealed that both 100 and 150 nmol doses reliably enhanced 1-h feeding, whereas 50 nmol did not. In experiment 3, tests of 90-min locomotor activity and water intake in the absence of food revealed that 100 nmol MET intraventricularly did not modify either behavior compared with vehicle infusions, suggesting a degree of feeding specificity to this effect. In an attempt to determine the site of intraventricular MET effects on feeding, experiment 4 tested 1-h feeding responses after 0, 5, 10, 20, 40, or 60 nmol MET were infused unilaterally into the paraventricular nucleus (PVN) of the hypothalamus. No reliable feeding was induced at any of these drug doses, although injections of 30 nmol norepinephrine (NE) were effective in doubling food intake. Experiment 5 further showed that bilateral infusions of 50 nmol MET in each PVN (total dose, 100 nmol) were ineffective in altering 1-h feeding. This contrasted markedly to the high potency of 15 nmol NE per site (total dose, 30 nmol), which elicited fivefold greater feeding than control infusions.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Ventrículos Cerebrais/fisiologia , Comportamento Alimentar/efeitos dos fármacos , Metergolina/farmacologia , Núcleo Hipotalâmico Paraventricular/fisiologia , Resposta de Saciedade/efeitos dos fármacos , Animais , Ventrículos Cerebrais/efeitos dos fármacos , Relação Dose-Resposta a Droga , Infusões Parenterais , Masculino , Metergolina/administração & dosagem , Especificidade de Órgãos , Núcleo Hipotalâmico Paraventricular/efeitos dos fármacos , Ratos , Ratos Wistar , Fatores de TempoRESUMO
In the present study, we investigated the effects of various serotonin (5-HT) antagonists on 5-HT's action on medial prefrontal cortical cells (mPFc) using the techniques of single cell recording and microiontophoresis. The microiontophoretic application of 5-HT (10-80 nA) produced a current-dependent suppression of mPFc cell firing and this effect was blocked by the selective 5-HT3 receptor antagonists (+/-)-zacopride, ICS 205930 and granisetron at currents of 5-20 nA. Furthermore, the intravenous (i.v.) administration of (+/-)-zacopride (5-50 micrograms/kg) markedly attenuates the suppressive action of 5-HT on mPFc cell firing. In contrast, the microiontophoresis of 5-HT1 and 5-HT2 receptor antagonists such as (+/-)-pindolol, spiperone, metergoline, and ritanserin (10-20 nA) failed to block 5-HT's effect. In fact, in some cells, spiperone and ritanserin potentiated 5-HT's action and prolonged neuronal recovery. In addition, the intravenous administration of either ritanserin (5-2,000 micrograms/kg) or metergoline (4-2,400 micrograms/kg) failed to alter 5-HT's action. The electrical stimulation of the caudal linear raphe nucleus (CLi) suppressed the spontaneous activity of 83% of the mPFc cells tested by 45 +/- 2%. This suppression was significantly attenuated by the iontophoresis of granisetron (2.5-5 nA) but not by the 5-HT2 and 5-HT1C receptor antagonist ritanserin or the relatively selective 5-HT2 receptor antagonist (+)-MDL 11,939 (10-40 nA). However, the i.v. administration of ritanserin (0.5-1.5 mg/kg) or S-zacopride (0.1 mg/kg) significantly blocked the suppression of mPFc cell firing produced by CLi stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes , Lobo Frontal/fisiologia , Receptores de Serotonina/fisiologia , Antagonistas da Serotonina/farmacologia , Serotonina/farmacologia , Análise de Variância , Animais , Benzamidas/administração & dosagem , Benzamidas/farmacologia , Compostos Bicíclicos com Pontes/administração & dosagem , Compostos Bicíclicos com Pontes/farmacologia , Lobo Frontal/efeitos dos fármacos , Indóis/administração & dosagem , Indóis/farmacologia , Injeções Intravenosas , Iontoforese , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Pindolol/administração & dosagem , Pindolol/farmacologia , Piperidinas/administração & dosagem , Piperidinas/farmacologia , Ratos , Ratos Endogâmicos , Receptores de Serotonina/efeitos dos fármacos , Ritanserina/administração & dosagem , Ritanserina/farmacologia , Serotonina/administração & dosagem , Antagonistas da Serotonina/administração & dosagem , Espiperona/administração & dosagem , Espiperona/farmacologia , TropizetronaRESUMO
The behavioural response to intrathecal serotonin (5-HT) was examined in mice after acute and after withdrawal of repeated treatment with the 5-HT uptake inhibitor zimelidine or the 5-HT receptor antagonist metergoline. Intrathecal 5-HT elicits a response consisting of biting or licking of the lower part of abdomen and reciprocal hindlimb scratching, indicative of nociceptive stimulation. Acute injection of zimelidine (20 mg/kg) significantly increased the response to intrathecal 5-HT (0.25-1 micrograms) whereas a single dose of metergoline (5 mg/kg) completely blocked the response to intrathecal 5-HT (2 micrograms). The behavioural response to intrathecal 5-HT (0.25-2 micrograms) was not significantly changed 48 hr after withdrawal of repeated treatment with zimelidine (2 x 10 mg/kg/day for 14 days) or metergoline (2 x 2.5 mg/kg/day for 14 days). In the present experiments acute zimelidine appeared to increase nociceptive responsiveness, whereas metergoline had the opposite effect. This study does not provide evidence that long-term treatment with zimelidine or metergoline leads to adaptive changes in the response to spinal cord 5-HT receptor stimulation.
Assuntos
Metergolina/farmacologia , Nociceptores/efeitos dos fármacos , Receptores de Serotonina/efeitos dos fármacos , Serotonina/farmacologia , Zimeldina/farmacologia , Animais , Injeções Intraperitoneais , Injeções Espinhais , Masculino , Metergolina/administração & dosagem , Camundongos , Dor/fisiopatologia , Serotonina/administração & dosagem , Zimeldina/administração & dosagemRESUMO
Interactions between 5-hydroxytryptamine (5-HT) and substance P (SP) in the mouse spinal cord were investigated using the tail-flick test and the behavioral response evoked by intrathecal (i.th.) SP or i.th. 5-HT. I.th. injection of 5-HT (20 micrograms) or the 5-HT1 receptor agonists (+)-8-hydroxy-2-(di-n-propylamino)tetralin ((+)-8-OH-DPAT) (20 micrograms) or 5-methoxy-3(1,2,3,6-tetrahydropyridine-4-yl)-1H-indole (RU 24969) (20 micrograms) markedly inhibited the tail-flick reflex. The effect of these compounds was reduced when SP (5 micrograms) was given i.th. 55 min, or 55 and 45 min before the agonists. The tail-flick latencies recorded 5 min before injection of a 5-HT receptor agonist were similar in animals treated with SP or vehicle. The changes in the tail-flick test were not due to changes in tail skin temperature since only minimal differences in the skin temperature were recorded between the groups injected with SP or vehicle. I.th. injection of SP (10 ng) or 5-HT (2 micrograms) produced a similar behavioral response consisting of biting, licking and scratching of the caudal part of the body, indicative of nociceptive stimulation. The responses both to i.th. SP and 5-HT were reduced after i.th. application of the SP receptor antagonist [D-Arg1,D-Trp7.9,Leu11]-SP (Spantide) (5 micrograms), as well as 5 min after i.th. injection of the 5-HT receptor antagonist metergoline (4 micrograms). The data may indicate functional interactions between SP and 5-HT in the mouse spinal cord, which may take place in neurons involved in the processing of nociception.
Assuntos
Neurônios/fisiologia , Dor/fisiopatologia , Serotonina/farmacologia , Medula Espinal/fisiologia , Substância P/farmacologia , 8-Hidroxi-2-(di-n-propilamino)tetralina , Analgésicos/farmacologia , Animais , Indóis/administração & dosagem , Indóis/farmacologia , Injeções Espinhais , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Camundongos , Camundongos Endogâmicos , Neurônios/efeitos dos fármacos , Serotonina/administração & dosagem , Antagonistas da Serotonina/farmacologia , Temperatura Cutânea/efeitos dos fármacos , Medula Espinal/efeitos dos fármacos , Medula Espinal/fisiopatologia , Substância P/administração & dosagem , Substância P/análogos & derivados , Tetra-Hidronaftalenos/administração & dosagem , Tetra-Hidronaftalenos/farmacologiaRESUMO
We examined in mice whether tail skin temperatures and tail-flick reflexes were changed after spinal transection or intrathecal (i.th.) injection of the serotonin (5-HT) neurotoxin 5,6-dihydroxytryptamine (5,6-DHT) or the 5-HT receptor antagonist metergoline. Transection of the spinal cord reduced tail-flick latency (the time needed to evoke the tail-flick reflex by radiant heat) and increased tail skin temperature 15-21 days after surgery. Analysis of covariance showed that the effect of tail skin temperature on tail-flick latency was far more pronounced than the effect of spinal transection. Intrathecal injection of 5,6-DHT (5 or 10 micrograms mouse-1), which extensively reduced the spinal levels of 5-HT, reduced tail-flick latency and increased tail skin temperature 1-5 days after treatment. Similarly, tail-flick latency was shortened and tail skin temperature elevated 15 min after i.th. injection of metergoline (0.5 micrograms mouse-1). Analysis of covariance showed no significant effect of i.th. 5,6-DHT or i.th. metergoline on tail-flick latency. Tail skin temperature, on the other hand, had a highly significant effect on tail-flick latency. The results show that the facilitation of the tail-flick reflex in spinally transected mice and mice injected i.th. with 5,6-DHT or metergoline is mainly caused by increased tail skin temperature. The data do not indicate that descending 5-HT pathways tonically inhibit the tail-flick reflex.
Assuntos
Receptores de Serotonina/fisiologia , Reflexo/fisiologia , Temperatura Cutânea , Medula Espinal/fisiologia , Transmissão Sináptica , Cauda/fisiologia , 5,6-Di-Hidroxitriptamina/administração & dosagem , Animais , Injeções Espinhais , Masculino , Metergolina/administração & dosagem , Camundongos , Camundongos Endogâmicos , Nociceptores/fisiologia , Receptores de Serotonina/efeitos dos fármacos , Serotonina/administração & dosagem , Temperatura Cutânea/efeitos dos fármacos , Transmissão Sináptica/efeitos dos fármacos , Cauda/inervaçãoRESUMO
The present studies were designed to investigate further the mechanism by which water intake is induced in rats by peripheral administration of either serotonin (5HT) or its precursor 5-hydroxytryptophan (5HTP). Consistent with previous studies that have implicated mediation by the renal renin-angiotensin system (RAS), we now report that bilateral nephrectomy completely abolishes the drinking response to various doses of 5HT. In contrast, nephrectomy had little effect on the drinking induced by 5HTP. Thus, 5HTP may induce drinking by mechanisms other than its peripheral conversion to 5HT and subsequent activation of the RAS. The drinking responses to both 5HT and 5HTP were blocked by peripheral administration of the 5HT receptor antagonist, metergoline, but the drug was at least ten-fold more potent against 5HTP than 5HT. Intracerebroventricular (ICV) administration of metergoline also prevented the drinking response to peripherally-administered 5HTP. The drinking responses to both 5HT and 5HTP were enhanced by peripheral administration of low doses of an angiotensin I converting enzyme inhibitor, captopril. Collectively, these findings support previous conclusions that 5HT-induced intake of water is mediated exclusively by the renal RAS. However, 5HTP-induced drinking may additionally involve a renin-independent, serotonin-mediated mechanism, possibly in the brain.
Assuntos
5-Hidroxitriptofano/farmacologia , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Serotonina/farmacologia , Animais , Captopril/farmacologia , Relação Dose-Resposta a Droga , Feminino , Injeções Intraventriculares , Injeções Subcutâneas , Masculino , Metergolina/administração & dosagem , Metergolina/farmacologia , Nefrectomia , Ratos , Ratos Endogâmicos , Fatores SexuaisRESUMO
The effect of fenfluramine on food-rewarded runway behaviour was studied in rats that had reached stable performance levels in a three-trials test procedure. d-Fenfluramine was about twice as potent as 1-fenfluramine in its influence on all aspects of runway behaviour: starting speed, running speed and the number of pellets eaten in each trial. Blockade of peripheral serotonin receptor sites by pretreatment with xylamidine, at a dose (2 mg/kg) blocking serotonin-induced inhibition of food intake, was unable to counteract the decrease in runway performance that resulted from treatment with either 2.5 mg/kg d-fenfluramine or 5.0 mg/kg 1-fenfluramine. However pretreatment with metergoline (2 mg/kg), an antagonist that affects both central and peripheral receptor sites, improved the performance of rats given these doses of d- and 1-fenfluramine. It is concluded that both isomers of fenfluramine affect food-rewarded runway behaviour through a mechanism that involves the stimulation of central but not peripheral serotoninergic pathways.